RxDoctor Payments Data

Stephanie Smith

Family · Cookeville, TNNPI 1104435353

Payments from drug & device makers

$14,262in general payments, 2019–2025

Across 820 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • Sumitomo Pharma America, Inc.$1K
  • Biogen$1K
  • AbbVie$1K
  • EMD Serono, Inc.$657
  • Lundbeck LLC$545
  • plus $8K from 51 others

What the payments were for

  • Food & beverage$13,64496%
  • Education$6184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.63$1,463
Sumitomo Pharma America, Inc.84$1,324
Biogen57$1,322
AbbVie74$1,074
EMD Serono, Inc.37$657
Lundbeck LLC28$545
Teva Pharmaceuticals USA, Inc.50$501
Novartis30$498
Pfizer32$487
SK Life Science, Inc.28$388
Jazz Pharmaceuticals Inc.15$381
Lilly USA, LLC23$368
Otsuka America Pharmaceutical, Inc.23$346
Corium, LLC15$326
AstraZeneca(2 entities)14$295
Johnson & Johnson19$282
Supernus Pharmaceuticals, Inc.18$278
Eisai Inc.16$270
Sunovion Pharmaceuticals Inc.21$263
Genentech USA, Inc.10$225
Biohaven Pharmaceutical Holding Company Ltd.11$217
Amneal Pharmaceuticals LLC10$212
Avanir Pharmaceuticals, Inc.12$209
Impel Pharmaceuticals Inc.18$175
MDD US Operations, LLC10$169
Neurocrine Biosciences, Inc.8$168
Amgen9$167
Sanofi8$153
Neurelis, Inc.8$127
Acadia Pharmaceuticals Inc6$122
Biohaven Pharmaceuticals, Inc.8$120
Harmony Biosciences LLC2$116
Bristol Myers Squibb6$113
Upsher-smith Laboratories LLC7$105
Ironshore Pharmaceuticals Inc.4$82
Argenx US, Inc.3$69
Avadel CNS Pharmaceuticals, LLC3$68
Vanda Pharmaceuticals Inc.3$66
Grifols USA, LLC3$65
Merck3$51
Kyowa Kirin, Inc.2$43
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$40
TG Therapeutics, Inc.2$37
Organon2$35
Impel Pharmaceuticals LLC1$25
Axsome Therapeutics, Inc.1$23
Sanofi-aventis U.S. LLC1$23
Sage Therapeutics, LLC1$22
Ipsen Biopharmaceuticals, Inc1$22
Tris Pharma Inc1$19
Arbor Pharmaceuticals, Inc.1$19
Inspire Medical Systems, Inc.1$19
Banner Life Sciences, LLC1$16
Collegium Pharmaceutical, Inc.1$16
Scilex Pharmaceuticals Inc.1$15
Tanabe Pharma America, Inc.1$12
Cycle Pharmaceuticals Inc1$9

How this compares

$14,262 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,292
Medicare patients
56
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab13$175,559
Nurtec OdtRimegepant Sulfate87$113,747
AptiomEslicarbazepine Acetate56$104,901
UbrelvyUbrogepant84$103,157
VumerityDiroximel Fumarate12$97,348
QuliptaAtogepant67$94,354
BriviactBrivaracetam58$86,314
CopaxoneGlatiramer Acetate12$85,418
VimpatLacosamide54$54,061
Aimovig AutoinjectorErenumab-Aooe69$50,232
ZonegranZonisamide13$25,829
TrileptalOxcarbazepine13$25,143
Emgality PenGalcanezumab-Gnlm20$18,020
Ajovy AutoinjectorFremanezumab-Vfrm18$16,255
FycompaPerampanel12$13,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,074$197,512151 claims
UCB, Inc.Briviact, Vimpat$1,463$140,375112 claims
PfizerNurtec Odt$487$113,74787 claims
Sunovion Pharmaceuticals Inc.Aptiom$263$104,90156 claims
BiogenVumerity$1,322$97,34812 claims
Teva Pharmaceuticals USA, Inc.Copaxone$501$85,41812 claims
Eisai Inc.Fycompa$270$13,18012 claims
Upsher-smith Laboratories LLCTopiramate$105$1,325100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →